



CMS

PHASE 1B STUDY

ARGX-119-2302

Treating Patients With DOK7 Congenital Myasthenic Syndromes?

Consider **referring** your patient to an interventional study:

“A Phase 1b, Double-Blinded, Randomized, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Efficacy of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)”

ARGX-119 is not approved by any regulatory agency for the treatment of patients with CMS as safety and efficacy have not been established.



or visit clinicaltrials.gov/study/NCT06436742 for more information